COMMUNITY HEALTHCARE TRUST I (CHCT) Stock Fundamental Analysis
NYSE:CHCT - New York Stock Exchange, Inc. - US20369C1062 - REIT - Currency: USD
Overall CHCT gets a fundamental rating of 3 out of 10. We evaluated CHCT against 129 industry peers in the Diversified REITs industry. CHCT may be in some trouble as it scores bad on both profitability and health. CHCT is valied quite expensively at the moment, while it does show a decent growth rate. CHCT also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
CHCT had negative earnings in the past year.
In the past year CHCT had a positive cash flow from operations.
Of the past 5 years CHCT 4 years were profitable.
CHCT had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of CHCT (-1.08%) is worse than 68.22% of its industry peers.
CHCT has a Return On Equity of -2.37%. This is in the lower half of the industry: CHCT underperforms 64.34% of its industry peers.
CHCT's Return On Invested Capital of 2.16% is in line compared to the rest of the industry. CHCT outperforms 40.31% of its industry peers.
CHCT had an Average Return On Invested Capital over the past 3 years of 2.59%. This is in line with the industry average of 3.07%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.08% | ||
| ROE | -2.37% | ||
| ROIC | 2.16% |
ROA(3y)0.71%
ROA(5y)1.48%
ROE(3y)1.2%
ROE(5y)2.39%
ROIC(3y)2.59%
ROIC(5y)2.93%
1.3 Margins
CHCT's Operating Margin of 22.02% is in line compared to the rest of the industry. CHCT outperforms 50.39% of its industry peers.
In the last couple of years the Operating Margin of CHCT has declined.
Looking at the Gross Margin, with a value of 80.40%, CHCT is in the better half of the industry, outperforming 79.84% of the companies in the same industry.
CHCT's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 22.02% | ||
| PM (TTM) | N/A | ||
| GM | 80.4% |
OM growth 3Y-9.56%
OM growth 5Y-2.62%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.21%
GM growth 5Y0.1%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), CHCT is destroying value.
CHCT has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CHCT has been increased compared to 5 years ago.
CHCT has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 0.78, we must say that CHCT is in the distress zone and has some risk of bankruptcy.
CHCT has a better Altman-Z score (0.78) than 67.44% of its industry peers.
CHCT has a debt to FCF ratio of 41.17. This is a negative value and a sign of low solvency as CHCT would need 41.17 years to pay back of all of its debts.
CHCT has a Debt to FCF ratio of 41.17. This is in the better half of the industry: CHCT outperforms 65.12% of its industry peers.
A Debt/Equity ratio of 1.15 is on the high side and indicates that CHCT has dependencies on debt financing.
CHCT's Debt to Equity ratio of 1.15 is in line compared to the rest of the industry. CHCT outperforms 54.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.15 | ||
| Debt/FCF | 41.17 | ||
| Altman-Z | 0.78 |
ROIC/WACC0.31
WACC7.02%
2.3 Liquidity
A Current Ratio of 0.59 indicates that CHCT may have some problems paying its short term obligations.
With a Current ratio value of 0.59, CHCT is not doing good in the industry: 75.19% of the companies in the same industry are doing better.
A Quick Ratio of 0.28 indicates that CHCT may have some problems paying its short term obligations.
CHCT's Quick ratio of 0.28 is on the low side compared to the rest of the industry. CHCT is outperformed by 86.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.59 | ||
| Quick Ratio | 0.28 |
3. Growth
3.1 Past
The earnings per share for CHCT have decreased strongly by -135.90% in the last year.
Measured over the past years, CHCT shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -10.22% on average per year.
The Revenue for CHCT has decreased by -18.01% in the past year. This is quite bad
CHCT shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.73% yearly.
EPS 1Y (TTM)-135.9%
EPS 3Y-37.5%
EPS 5Y-10.22%
EPS Q2Q%-1350%
Revenue 1Y (TTM)-18.01%
Revenue growth 3Y8.53%
Revenue growth 5Y13.73%
Sales Q2Q%9.49%
3.2 Future
The Earnings Per Share is expected to grow by 41.23% on average over the next years. This is a very strong growth
Based on estimates for the next years, CHCT will show a quite strong growth in Revenue. The Revenue will grow by 9.17% on average per year.
EPS Next Y-51.43%
EPS Next 2Y47.84%
EPS Next 3Y41.23%
EPS Next 5YN/A
Revenue Next Year5.45%
Revenue Next 2Y6.49%
Revenue Next 3Y8.3%
Revenue Next 5Y9.17%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CHCT. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 32.07, CHCT can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, CHCT is valued a bit cheaper than the industry average as 73.64% of the companies are valued more expensively.
CHCT is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 35.24, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 32.07 |
4.2 Price Multiples
CHCT's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. CHCT is cheaper than 61.24% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, CHCT is valued a bit cheaper than 66.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 34.16 | ||
| EV/EBITDA | 13.07 |
4.3 Compensation for Growth
A more expensive valuation may be justified as CHCT's earnings are expected to grow with 41.23% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y47.84%
EPS Next 3Y41.23%
5. Dividend
5.1 Amount
CHCT has a Yearly Dividend Yield of 12.94%, which is a nice return.
Compared to an average industry Dividend Yield of 6.54, CHCT pays a better dividend. On top of this CHCT pays more dividend than 96.12% of the companies listed in the same industry.
CHCT's Dividend Yield is rather good when compared to the S&P500 average which is at 2.36.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 12.94% |
5.2 History
The dividend of CHCT has a limited annual growth rate of 2.99%.
CHCT has paid a dividend for at least 10 years, which is a reliable track record.
As CHCT did not decrease their dividend in the past 5 years, we can say the dividend looks stable.
Dividend Growth(5Y)2.99%
Div Incr Years9
Div Non Decr Years9
5.3 Sustainability
CHCT has negative earnings and hence a negative payout ratio. The dividend may be in danger.
The dividend of CHCT is growing, but earnings are growing more, so the dividend growth is sustainable.
DP-508.87%
EPS Next 2Y47.84%
EPS Next 3Y41.23%
NYSE:CHCT (8/19/2025, 2:04:13 PM)
14.72
+0.26 (+1.8%)
Chartmill FA Rating
GICS SectorReal Estate
GICS IndustryGroupEquity Real Estate Investment Trusts (REITs)
GICS IndustryDiversified REITs
Earnings (Last)
Earnings (Next)
Inst Owners86.5%
Inst Owner Change-0.87%
Ins Owners5.63%
Ins Owner Change7.27%
Market Cap417.61M
Analysts81.82
Price Target20.5 (39.27%)
Short Float %2.49%
Short Ratio2.3
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 12.94% |
Yearly Dividend1.85
Dividend Growth(5Y)2.99%
DP-508.87%
Div Incr Years9
Div Non Decr Years9
Ex-Date
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-73.26%
Min EPS beat(2)-88.54%
Max EPS beat(2)-57.98%
EPS beat(4)0
Avg EPS beat(4)-58.62%
Min EPS beat(4)-88.54%
Max EPS beat(4)-43.98%
EPS beat(8)0
Avg EPS beat(8)-52.43%
EPS beat(12)1
Avg EPS beat(12)-56.5%
EPS beat(16)1
Avg EPS beat(16)-45.99%
Revenue beat(2)0
Avg Revenue beat(2)-1.5%
Min Revenue beat(2)-2.49%
Max Revenue beat(2)-0.52%
Revenue beat(4)0
Avg Revenue beat(4)-2.06%
Min Revenue beat(4)-3.64%
Max Revenue beat(4)-0.52%
Revenue beat(8)0
Avg Revenue beat(8)-3.6%
Revenue beat(12)1
Avg Revenue beat(12)-2.85%
Revenue beat(16)2
Avg Revenue beat(16)-2.63%
PT rev (1m)-1.95%
PT rev (3m)-5.19%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-20%
EPS NY rev (1m)0%
EPS NY rev (3m)-72.97%
Revenue NQ rev (1m)-0.23%
Revenue NQ rev (3m)-3.43%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.5%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 32.07 | ||
| P/S | 3.54 | ||
| P/FCF | 34.16 | ||
| P/OCF | 7.24 | ||
| P/B | 0.95 | ||
| P/tB | 0.96 | ||
| EV/EBITDA | 13.07 |
EPS(TTM)-0.14
EYN/A
EPS(NY)0.46
Fwd EY3.12%
FCF(TTM)0.43
FCFY2.93%
OCF(TTM)2.03
OCFY13.82%
SpS4.16
BVpS15.43
TBVpS15.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.08% | ||
| ROE | -2.37% | ||
| ROCE | 2.74% | ||
| ROIC | 2.16% | ||
| ROICexc | 2.18% | ||
| ROICexgc | 2.21% | ||
| OM | 22.02% | ||
| PM (TTM) | N/A | ||
| GM | 80.4% | ||
| FCFM | 10.35% |
ROA(3y)0.71%
ROA(5y)1.48%
ROE(3y)1.2%
ROE(5y)2.39%
ROIC(3y)2.59%
ROIC(5y)2.93%
ROICexc(3y)2.61%
ROICexc(5y)2.94%
ROICexgc(3y)2.69%
ROICexgc(5y)3%
ROCE(3y)3.28%
ROCE(5y)3.7%
ROICexcg growth 3Y-9.66%
ROICexcg growth 5Y-0.75%
ROICexc growth 3Y-10.19%
ROICexc growth 5Y-1.2%
OM growth 3Y-9.56%
OM growth 5Y-2.62%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.21%
GM growth 5Y0.1%
F-Score3
Asset Turnover0.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.15 | ||
| Debt/FCF | 41.17 | ||
| Debt/EBITDA | 7.24 | ||
| Cap/Depr | 104.47% | ||
| Cap/Sales | 38.52% | ||
| Interest Coverage | 1.05 | ||
| Cash Conversion | 82.99% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.59 | ||
| Quick Ratio | 0.28 | ||
| Altman-Z | 0.78 |
F-Score3
WACC7.02%
ROIC/WACC0.31
Cap/Depr(3y)284.94%
Cap/Depr(5y)339.12%
Cap/Sales(3y)99.29%
Cap/Sales(5y)115.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-135.9%
EPS 3Y-37.5%
EPS 5Y-10.22%
EPS Q2Q%-1350%
EPS Next Y-51.43%
EPS Next 2Y47.84%
EPS Next 3Y41.23%
EPS Next 5YN/A
Revenue 1Y (TTM)-18.01%
Revenue growth 3Y8.53%
Revenue growth 5Y13.73%
Sales Q2Q%9.49%
Revenue Next Year5.45%
Revenue Next 2Y6.49%
Revenue Next 3Y8.3%
Revenue Next 5Y9.17%
EBIT growth 1Y-37.86%
EBIT growth 3Y-1.85%
EBIT growth 5Y10.76%
EBIT Next Year263.34%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y119.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4.01%
OCF growth 3Y1.48%
OCF growth 5Y12.72%